Trial · NCT07258914
Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)
NCT07258914, Not applicable, Recruiting, Hospital Center Guillaume Régnier
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD). Trials, record NCT07258914. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07258914
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)
- NCT number
- NCT07258914
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Hospital Center Guillaume Régnier
- Conditions
- Autism Spectrum Disorder, Depression, Major Depressive Episode (MDE)
- Interventions
- rTMS, rTMS treatment with intermittent Theta Burst (ITBS)
- First posted
- 2025-12-02
- Last updated
- 2025-12-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference in MADRS (Montgomery-Asberg Depression Rating Scale ) score before versus after treatment. | From enrollment to the end of the data collecting process : 2 months. | Upon inclusion, patients are assessed for mood using the MADRS.(inclusion criterion: MADRS\>20). The primary endpoint is the change in MADRS score one week after the end of treatment and one month after the end of treatment. score ranges from 0 to 60. The higher the score, the more severe the disorder is. |
| Secondary | Assessment of changes in irritability before versus after treatment | from enrolment to one month after the end of the rTMS treatment | Irritability is assessed with the Angst scale. A global score of 10 or more indicates irritability. |
| Secondary | assessment of changes in attention functions | From enrolment to one week then 1 month after the end of the rTMS treatment | Attentional functions are assessed using two subtests of the TAP (Test of Attentional Performance): * sustained attention : The test measures the ability to maintain attention over the long term with a high density of target stimuli. * Split Attention : The test explores the Ability to focus attention on two tasks simultaneously. |
| Secondary | Evolution of any side effects | During the treatment, at each stimulation time | Assessment of side effects of rTMS using the UKU scale |
| Secondary | Assement of change in repetitive behaviors before versus after treatment | from enrolment and 1 month after the end of rTMS treatment | BPI-1 (Behavior Problems Inventory) is an informant-based behaviour rating instrument that was designed to assess maladaptive behaviours in individuals with ASD. Its items fall into one of three sub-scales: Self-injurious Behavior (14 items), Stereotyped Behavior (24 items), and Aggressive/Destructive Behavior (11 items). Each item is rated on a frequency scale (0 = never to 4 = hourly), and a severity scale (0 = no problem to 3 = severe problem). |
| Secondary | assessment of changes in mood aspects in terms of psychomotor decline before versus after rTMS treatment | from enrolment to one week then one month after the end of the rTMS treatment | psychomotor decline is assessed with the depressive decline scale (ERD).This tool contains 14 items that describe the motor, verbal, ideational, hedonic, and cognitive behavior of depressed individuals. Each item is rated from 0 to 4 ( 1 expressing doubt about the pathological nature of the observed phenomenon). |
| Secondary | assessment of changes in mood aspects in terms of depression before versus after rTMS treatment | From enrolment to one week then one month after the end of the rTMS treatment | Depression is assessed with the Patient Health Questionnaire - 9 items (PHQ-9) This is a brief tool used to assess and measure the severity of depression. Items are rated on a scale from 0 to 3. The maximum score is 27 (major depression) |
| Secondary | Assessment of changes in executive functions before versus after rTMS treatment | From enrolment and 1 month after the end of rTMS treatment | The TMT (Trial Making Test) measures attention, visual screening ability, and processing speed. The Trail Making Test is scored by how long it takes to complete the test |
| Secondary | Assessment of changes in executive functions before versus after rTMS treatment | From enrolment and 1 month after the end of rTMS treatment | The Stroop test measures recognition reaction times to color stimuli, evaluating psychomotor speed and cognitive flexibility. |
| Secondary | Assessment of changes in executive functions before versus after rTMS treatment | From enrolment and 1 month after the end of rTMS treatment | The GO/NO GO task measures the ability to inhibit and the control of impulses |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Go/No-Go Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07258914
GET https://conductscience.org/api/trials/v1/NCT07258914/registered